Close Menu

Webinar/Video Library

Partner Webinar

Watch this webinar to see how DNAnexus Apollo empowers clinician researchers and bioinformaticians to work together to:

- Explore expansive TCGA clinical data elements with the Apollo Cohort Browser
- Identify, compare, and save cohorts of TCGA individuals that meet key phenotypic criteria
- Launch detailed analysis of genomic features of TCGA cohorts using the embedded Apollo JupyterLab environment, including:
     - Differential gene expression analysis
     - Visualization of mutational landscapes of case and control cohorts
     - Correlating genomic features with TCGA overall survival data

Sponsored by
Partner Webinar

Watch this webinar to learn how DNAnexus Apollo empowers UK Biobank researchers to:

-Explore possible correlations across population-wide genomic and phenotypic data

-Easily create and compare the genetic and phenotypic features of custom cohorts

-Investigate characteristics of a cohort of individuals who carry the same genetic variant

-Quickly conduct sophisticated, iterative analyses of cohort data using the embedded JupyterLab environment

Sponsored by
July 30, 2020
Sponsored by
PerkinElmer

Choosing a Coronavirus PCR Assay

Partner Webinar

Sleep Better Without Testing Nightmares:
Critical considerations when choosing an RT-PCR Assay for SARS-CoV-2 Testing.

Sponsored by
Partner Webinar

Focused panels that deliver rapid AI-driven insights - In this webinar we present Fabric Hereditary Panels with ACE and explore how these curated Fabric Enterprise gene panels accelerate your genomic interpretation and reporting. ACE is currently available for over 90 genes in the most commonly used genetic testing panels.

Sponsored by
GenomeWebinar

“If we build it, they will come” is a familiar refrain that echoes in life science entrepreneurial circles. Too frequently startups believe that if a technology is built it will sell. But the chasm that exists between a great technology and an executable go-to-market strategy is large. This webinar will break down the steps to build a branding and marketing approach needed to precede a new product rollout in the life science marketplace.

Will Gould, President and CSO of Brand Buddha, will break down the process of message development, audience segmentation, and how to target the right person, with the right message, in the right place, at the right time. Deb Franko, Principal of boutique healthcare marketing communications agency Karmic Health Communications, will provide insight into how to raise consumer awareness and drive patient adoption of new oncology solutions.

Together they will discuss how to develop a go-to-market strategy mapping all touchpoints from pre-awareness through to completed sale.

In this webinar you will learn:

  • How to find your audience and potential clients
  • How to develop branding and messaging that will resonate with your audience
  • How to put that message in front of your audience and the right time and in the right place
  • How to graduate your audience from pre-awareness to converted client
Sponsored by
GenomeWebinar

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Takayuki Takahama of Kindai Nara University Hospital will share details of the study, which enrolled 276 patients with advanced or recurrent NSCLC with known TKI-sensitizing mutations of EGFR, had documented disease progression after treatment with at least 1 first- or second-generation EGFR TKI, and were positive for the T790M mutation in plasma.

Dr. Takahama will discuss the results, which demonstrate the utility of liquid biopsy for the detection of T790M with the cobas EGFR Mutation Test v2. Plasma genotyping with this assay is informative for treatment selection in clinical practice when tumor sampling is not feasible. 

Sponsored by
GenomeWebinar

This webinar is the second in a three part series that will provide an overview of how cutting-edge genomic technologies based on next-generation sequencing (NGS) are streamlining in vitro fertilization research workflows*. 

Luis A. Alcaraz, cofounder of Bioarray and Journey Genomics, accredited diagnostic and research labs based in Alicante, Spain, will review how his teams use advanced genomic techniques for carrier screening research as well as for preimplantation genetic testing (PGT) in embryos for both aneuploidies (PGT-A) and monogenic disorders (PGT-M).

These technologies deliver greater efficiency to Bioarray and Journey Genomics, allowing faster delivery of meaningful results and reports for geneticists and researchers, which in turn is increasing their customer outcomes. 

In this webinar you will learn:

  • How to study PGT-A and PGT-M with NGS  
  • How expanded carrier screening with NGS screens for 420 genes in a single assay
  • How new molecular techniques are improving workflows at Bioarray and Journey Genomics

*For research use only. Not for use in diagnostic procedures.

Sponsored by
July 21, 2020
Sponsored by
Fabric Genomics

Near-Instant Identification of Rare Genetic Disease Genes

Partner Webinar

In this webinar, Francisco De La Vega, Chief Scientific Officer at Fabric Genomics,  will introduce the Fabric GEM AI algorithm and demonstrate how it significantly simplifies and improves disease-causing variant identification over prior methods. Dr. De La Vega will also show how Fabric GEM substantially reduces genome interpretation time in the diagnosis of monogenic disease and enables cost-effective, automated reanalysis of undiagnosed cases over time.

Sponsored by
GenomeWebinar

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response

Digital spatial profiling of immuno-oncology targets in the tumor, microenvironment, and immune compartments of archival formalin-fixed, paraffin-embedded tissue sections is coupled to downstream next-generation sequencing (NGS) readout. Our speakers will discuss how the NGS readout enables high-throughput and high-plex spatial analysis.

Our first speaker, Margaret Hoang, Senior Scientist, NanoString Technologies will provide a high level overview of the GeoMx Digital Spatial Profiler (DSP), which delivers quantitative high plex, multi-analyte spatial profiling using NGS readout.

Maija Kiuru of the University of California, Davis, will share details of a study that used NanoString’s GeoMx Cancer Transcriptome Atlas to reveal microenvironment-specific expression of a novel cell-type specific biomarker, DAMP, in response to early melanoma development. This marker may allow for more sensitive detection of melanoma via patch biopsy. 

William Hwang of the Broad Institute will then discuss how his team used GeoMx Cancer Transcriptome Atlas and Whole Transcriptome Atlas applications to profile tumor, fibroblast, and immune compartments in pancreatic ductal adenocarcinoma (PDAC) samples from twelve patients. Differential gene expression was measured in tumor and fibroblast compartments between treatment groups and by levels of immune infiltration.

Sponsored by
Partner Webinar

Associate Director Project Management OEM at QIAGEN 

The Regulation of the European Union with regards to the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) , adopted to improve the protection of human health and the environment from the risks that can be posed by industrial use of chemicals, is relevant to QIAGEN and its OEM partners. Octylphenol ethoxylates (OPE), such as Triton X-100, and nonylphenol ethoxylates (NPE) are detergents widely used in molecular biology. They were included in the European Authorisation list (Annex XIV). Therefore their use by manufactures and end-users will be highly regulated inside the EU in the near future. QIAGENs ongoing efforts in strengthening relationships with third parties in the OEM business include the compliance with existing and upcoming regulations from various authorities. In this Webinar, the implications of the REACH Regulation especially for OEM partners will be reviewed along with OEM by QIAGEN’s strategy and ongoing activities to assure future supply and compliance.

About the speaker: Dr. Frank Narz is Associate Director Project Management OEM at QIAGEN in Hilden. He works at the interface between OEM partners and QIAGEN internal stakeholders to implement new products and support existing cooperations. Dr. Narz joined QIAGEN in 2000 and has since held various positions in Research and Development in areas like RNA purification, cell biology or assay technologies and is since 2019 a member of the OEM by QIAGEN team. After studying biology, he received his Ph.D. from the Institute of Molecular Neurobiochemistry at the Faculty for Chemistry (University of Bochum, Germany) in 1999. He also completed postgraduate studies in Nanobiotechnology at the University Kaiserslautern in Germany.

Sponsored by
July 15, 2020
Sponsored by
LGC SeraCare Life Sciences

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

GenomeWebinar

Chief Scientific Officer, Foundation Medicine

Global Head of Medical Affairs,
Clinical NGS and Oncology Division, Thermo Fisher Scientific

President & Chief Technology Officer,  Genosity

Vice President, Assay Development, Illumina

Chief Scientific Officer, LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer. However, only a minority of patients with terminal cancer have durable response with approved immuno-oncology treatments.

This on-demand webinar features a panel of experts in the field who provide key insights into the current advances in cancer diagnostics and immunotherapy, as well as challenges facing the discipline.

The panelists bring a wealth of expertise and differing viewpoints in clinical laboratory practice, cancer research, translational sciences, and immuno-oncology diagnostics and therapeutics at the molecular and cellular levels important to the care and management of cancer patients and treatment outcomes. Each speaker will have an opportunity to share their perspectives on this topic, which will be moderated by Dr. Russell Garlick, Chief Scientific Officer at LGC SeraCare. The presentation will be followed by a live Q&A to allow attendees to address the experts directly.

Sponsored by
GenomeWebinar

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

The assay under development at the University of Pennsylvania is based on a microarray platform of 8 arrays by 60,000 probes and detects all known viruses and other pathogenic bacteria, fungi, and parasites, covering more than 6,000 accessions of microorganisms associated with diseases.

The array-based technology can accurately detect an agent of interest, including SARS-CoV-2, in less than 24 hours. The assay includes probes covering all known pathogenic respiratory pathogens, including other coronaviruses from bats and other mammals, providing accurate and efficient detection of SARS-CoV-2 as well as the potential for detection of other respiratory pathogens as co-infecting agents that may contribute to severity of disease. 

Dr. Erle Robertson of the University of Pennsylvania will describe the benefits of the test, which include high accuracy due to the use of multiple probes across the genome, which minimizes negative results from probe failure due to the compensatory signals from other probes in the assay screen. 

Dr. Robertson will discuss his team’s plans to develop the assay to require only a few drops of blood or plasma for detection of the virus.    

Disclaimer: Agilent products are NOT approved for COVID-19 testing, diagnosis, treatment, or mitigation. Agilent has not validated a product to detect the novel coronavirus.

For Research Use Only. Not for use in diagnostic procedures.

Sponsored by
GenomeWebinar

In this webinar, Dr. Charlie Johnson, founder of the Texas A&M AgriLife Genomics and Bioinformatics Service, will share how his team is utilizing Illumina’s DRAGEN informatics platform in its high-throughput agrigenomics research program. 

Increases in sequencing power, laboratory automation, and bioinformatics have revolutionized agriculture genomics, but until the rise of the DRAGEN system, computing was the biggest roadblock for Dr. Johnson’s team. He will discuss how the platform has enabled his lab to reduce post-run data processing time from days to hours and in some cases minutes.

Dr. Johnson will also share how his team has expanded use of the DRAGEN system across the whole analysis pipeline, describe areas where the power of the platform’s hardware acceleration provides the best performance, and outline work being done to further improve efficiency.

Illumina’s Stephanie Black will review the DRAGEN technology, discuss key application areas, summarize recent advancements, and walk through the growing DRAGEN access points, both on-premises and in the cloud.

Sponsored by
Partner Webinar

In this webinar, you will discover the power of HGMD Professional and see why reference labs around the world, such as LabCorp and Genomics England, use HGMD Professional in their clinical test interpretation. Through a live demonstration, you will learn how to use the online interface and downloadable database, as well as how to use HGMD Professional and ANNOVAR to produce a powerful in-house variant interpretation solution.

Sponsored by
Partner Webinar

The remarkable advances in precision medicine are unfortunately not currently available to all patients, especially those being treated in community cancer settings. This growing “gap” is now challenging the health system to provide cost-effective, scalable, innovative solutions for underserved patients. Protean BioDiagnostics was founded to close this gap and accelerate access to precision oncology for all patients, regardless of where they live. To this end, Protean has created an adaptable and innovative framework for rapidly deploying the latest companion diagnostics. Protean’s simplification of universal access to complex diagnostics is poised to change the practice of precision oncology in the community and truly “close the gap.”

In this webinar, you will learn more about

  1. Protean’s proprietary, multi-omic, data-centric Oncology MAPS™ system and how the system creates an easy way for oncologists and patients to access the latest evidence-based diagnostics, guideline-driven therapeutics, and new clinical trials.
  2. How QIAGEN’s bioinformatics team and Protean are working together to successfully deploy WES into clinical practice and give practitioners the knowledge to improve disease risk management and select treatment.
  3. Protean’s goal of maintaining and managing genetic and other medical data for patients in MAPS™ system, which enables this complex genetic data to become both “future-protected” and an enduring legacy for the patient, and their family.
Sponsored by

Pages

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Noel Rose, the "father of autoimmunity," has died at 92, the Washington Post reports.

According to CNN, Legionella was discovered in buildings leased by the Centers for Disease Control and Prevention as they reopened following coronavirus pandemic-related closures.

In PLOS this week: genetic analysis of malaria parasite populations in Southeast Asia, genomic surveillance of yellow fever virus in São Paulo, and more.

Interested in Posting your Webinar or White Paper on GenomeWeb?

Contact us